Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers.

McIlleron H, Norman J, Kanyok TP, Fourie PB, Horton J, Smith PJ.

J Antimicrob Chemother. 2007 Dec;60(6):1398-401. Epub 2007 Oct 20.

PMID:
17951604
2.

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.

Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.

Int J Clin Pharmacol Ther. 2002 Oct;40(10):474-81.

PMID:
12395981
3.

Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.

Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.

Clin Ther. 2013 Feb;35(2):161-8. doi: 10.1016/j.clinthera.2013.01.003.

PMID:
23410999
4.
5.

Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.

Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.

Int J Pharm. 2002 Feb 21;233(1-2):169-77.

PMID:
11897421
6.

Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.

Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.

Int J Tuberc Lung Dis. 1998 Oct;2(10):824-30.

PMID:
9783530
7.

Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.

Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL.

Pharmacol Res. 2003 Oct;48(4):383-7.

PMID:
12902209
8.

Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.

Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ.

Int J Pharm. 2001 Oct 9;228(1-2):53-67.

PMID:
11576768
9.

The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.

Zwolska Z, Augustynowicz-Kopeć E, Niemirowska-Mikulska H.

Acta Pol Pharm. 2002 Nov-Dec;59(6):448-52.

10.

Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.

Roy V, Tekur U, Chopra K.

Indian Pediatr. 1996 Apr;33(4):287-91.

PMID:
8772902
11.

Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.

Wang HF, Wang R, O'Gorman M, Crownover P, Naqvi A, Jafri I.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1596-601. doi: 10.5588/ijtld.13.0190.

PMID:
24200275
12.

The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.

De Rosa HJ, Baldan HM, Brunetti IL, Ximenes VF, Machado RG.

Biopharm Drug Dispos. 2007 Sep;28(6):291-6.

PMID:
17571294
13.
14.

Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.

Panchagnula R, Kaur KJ, Singh I, Kaul CL.

Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):689-94.

PMID:
11294011
15.

A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.

Singh S, Mohan B.

Int J Tuberc Lung Dis. 2003 Mar;7(3):298-303.

PMID:
12661847
16.

Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.

Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.

Int J Tuberc Lung Dis. 1999 Feb;3(2):119-25.

PMID:
10091876
17.

Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs.

Immanuel C, Gurumurthy P, Ramachandran G, Venkatesan P, Chandrasekaran V, Prabhakar R.

Indian J Med Res. 2003 Sep;118:109-14.

PMID:
14700343
18.
19.

Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.

Padgaonkar KA, Revankar SN, Bhatt AD, Vaz JA, Desai ND, D'Sa S, Shah V, Gandewar K.

Int J Tuberc Lung Dis. 1999 Jul;3(7):627-31.

PMID:
10423226
20.

[Results of examination in healthy volunteers of rifampicin and isoniazid bioavailability from Polish two-drug combination capsules of rifamazid used for tuberculosis treatment].

Zofia Z, Niemirowska-Mikulska H, Augustynowicz-Kopeć E, Stambrowska A.

Pneumonol Alergol Pol. 1998;66(3-4):198-206. Polish.

PMID:
9857665

Supplemental Content

Support Center